Your Search Results

How to face resistent hypertension: when pharmacological treatment is not an option

19 May 2026 – From EuroPCR 2026

Focused on resistant hypertension, this session explores interventional options when pharmacological treatments fall short. It discusses urgent intervention indications, complex cases involving renal artery occlusion, and the role of fractional flow reserve (FFR) in managing pan-vascular disease associated with hypertension.

FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case

19 May 2026 – From EuroPCR 2026

A 71‑year‑old man with hypertension and dyslipidemia presented with CCS class II angina and three‑vessel coronary artery disease. Functional assessment included CT‑derived micro‑FFR, angiography‑based FFR, and stress myocardial scintigraphy. The only hemodynamically significant lesion was a long, calcified lesion of the LAD.

Lesion preparation was performed with...

FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case

TAVI procedural complications - Part 3: vascular complications, coronary issues and more

19 May 2026 – From EuroPCR 2026

This session addresses critical procedural complications during TAVI, emphasizing vascular issues, coronary complications, and complex bailout scenarios. Through challenging case examples, it offers insights into the management and anticipation of such complications to optimize patient outcomes.

Identifying problems and solving complex anatomies during TAVI

19 May 2026 – From EuroPCR 2026

A comprehensive session on managing complex anatomies during Transcatheter Aortic Valve Implantation (TAVI), emphasizing risk markers for peri-operative complications and strategies to address difficult anatomical challenges. Real-world cases illustrate practical approaches and key learnings for handling intricate TAVI scenarios.

Calcified coronary: LIVE Educational Case from Clinique Pasteur - Toulouse, France

20 May 2026 – From EuroPCR 2026

This live educational case from Clinique Pasteur in Toulouse, France, showcases the management of complex calcified coronary lesions through multimodality imaging guidance. It addresses the selection of plaque modification devices and discusses optimal stenting strategies for challenging calcified bifurcation lesions, complemented by live procedural insights and...

OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease

04 Nov 2021

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Author

Mirvat Alasnag

OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?

02 Sep 2024

Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.

Author

Luis Ortega-Paz

Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials

14 Nov 2021

Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.

Author

Vijay Kunadian

ESC/EACTS Valvular Heart Disease Guidelines 2021: updates from the 2017 Guidelines

29 Aug 2021

There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...

Author

Mirvat Alasnag

Evidence base: current data on TAVI durability and long-term outcomes

18 Jun 2026

This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.